Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence

Bladder cancer is a prevalent disease, and treatment options for advanced bladder cancer remain limited. However, immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) have shown promise in treating bladder cancer. These...

Descripción completa

Detalles Bibliográficos
Autores principales: Okobi, Tobechukwu J, Uhomoibhi, Trinitas Oserefuamen, Akahara, Darlington E, Odoma, Victor A, Sanusi, Ibilola A, Okobi, Okelue E, Umana, Ifiok, Okobi, Emeka, Okonkwo, Chinwe C, Harry, Nkechinyere M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323982/
https://www.ncbi.nlm.nih.gov/pubmed/37425564
http://dx.doi.org/10.7759/cureus.40031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323982/
https://www.ncbi.nlm.nih.gov/pubmed/37425564
http://dx.doi.org/10.7759/cureus.40031

Ejemplares similares